JP4874686B2 - Anti-wrinkle / improving agent - Google Patents
Anti-wrinkle / improving agent Download PDFInfo
- Publication number
- JP4874686B2 JP4874686B2 JP2006084879A JP2006084879A JP4874686B2 JP 4874686 B2 JP4874686 B2 JP 4874686B2 JP 2006084879 A JP2006084879 A JP 2006084879A JP 2006084879 A JP2006084879 A JP 2006084879A JP 4874686 B2 JP4874686 B2 JP 4874686B2
- Authority
- JP
- Japan
- Prior art keywords
- wrinkle
- phase
- wrinkles
- wrinkle prevention
- improving agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001153 anti-wrinkle effect Effects 0.000 title 1
- 230000037330 wrinkle prevention Effects 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical class NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 description 42
- 239000012071 phase Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- -1 aminosulfuric acid compound Chemical class 0.000 description 28
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 230000006872 improvement Effects 0.000 description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 20
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000006071 cream Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 11
- 229920002125 Sokalan® Polymers 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 235000011118 potassium hydroxide Nutrition 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 229940099259 vaseline Drugs 0.000 description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000002304 perfume Substances 0.000 description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 6
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 6
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 230000009759 skin aging Effects 0.000 description 6
- 229940042585 tocopherol acetate Drugs 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 229960000735 docosanol Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940072106 hydroxystearate Drugs 0.000 description 3
- 229940119170 jojoba wax Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 3
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- 229960005066 trisodium edetate Drugs 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CRBBOOXGHMTWOC-NPDDRXJXSA-N 1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OCCO)[C@H]1OCCO CRBBOOXGHMTWOC-NPDDRXJXSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GGPORGHJKBOGDV-UHFFFAOYSA-M sodium;3-(cyclohexylamino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CNC1CCCCC1 GGPORGHJKBOGDV-UHFFFAOYSA-M 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
Description
本発明は皮膚のしわの発生を抑制し、生じたしわを改善する効果を有する安全性に優れたしわ防止・改善剤に関する。 The present invention relates to a wrinkle prevention / improving agent excellent in safety and having an effect of suppressing the generation of wrinkles on the skin and improving the generated wrinkles.
老化は全身の臓器で進行しているが、その中でも目で見ることができる皮膚、とりわけ特に意識が集中しやすい顔面については、老化とともに発生するしわ及び小じわが、世の多くの中高年齢者、とりわけ女性を悩ませている。従来、しわ改善用化粧料の必要性が叫ばれてきていたが、老化及びしわに関するメカニズムについて明らかではない部分が多かったため、従来の化粧料においては、ムコ多糖類やコラーゲン等の生化学製品及び合成高分子製品を配合してしわ改善のための水分保持に努めるという方法を選択してきたに過ぎない。 Aging is progressing in the organs of the whole body, but among the skin that can be seen with eyes, especially on the face where the consciousness is particularly concentrated, wrinkles and fine wrinkles that occur with aging are many middle-aged people in the world, Especially annoying women. Conventionally, the necessity of a wrinkle-improving cosmetic material has been screamed, but since there are many parts that are not clear about the mechanisms related to aging and wrinkles, in conventional cosmetics, biochemical products such as mucopolysaccharides and collagen and They have only selected a method of blending synthetic polymer products and trying to retain moisture to improve wrinkles.
しかしながら、上記の方法だけでは、皮膚の老化及びしわの発生を充分に防止することができない。近年、老化に関する研究が進められ、皮膚老化の原因としてマクロ的に見れば加齢が重要な因子であり、さらに乾燥、酸化、太陽光(紫外線)等も皮膚老化に関わる直接的な因子として挙げられてきている。それら因子の中でも太陽光(紫外線)は、光老化と呼ばれる変化において重要な役割を果たしていることが明らかとなってきた。上に記した顔面は、全身で最も光老化が進行しやすい部位であるが、光老化した皮膚では真皮の最も主要なマトリックス成分であるコラーゲン線維が著明に減少していることも明らかとなってきた。そしてしわ・小じわの発生、ハリの消失といった現象がコラーゲン線維の減少と密接に関係していることも示唆されてきている。このように、しわの発生及び皮膚老化に関しては、様々な皮膚老化因子、中でも太陽光(紫外線)曝露に伴い、真皮における主要な細胞である線維芽細胞の増殖活性やコラーゲン等の合成機能が低下して、このコラーゲン等のターンオーバー速度も遅くなる。その結果として、皮膚の弾力がなくなり、しわが発生し、皮膚の老化が進行する。 However, the above method alone cannot sufficiently prevent skin aging and wrinkles. In recent years, research on aging has been promoted, and aging is an important factor as a cause of skin aging, and dryness, oxidation, sunlight (ultraviolet rays), etc. are also cited as direct factors related to skin aging. It has been. Among these factors, it has become clear that sunlight (ultraviolet rays) plays an important role in a change called photoaging. The face described above is the most prone to photoaging in the whole body, but it is also clear that collagen fibers, which are the main matrix components of the dermis, are markedly reduced in photoaged skin. I came. It has also been suggested that phenomena such as the generation of wrinkles and fine lines and the disappearance of tension are closely related to the decrease in collagen fibers. Thus, with regard to wrinkle generation and skin aging, the proliferation activity of fibroblasts, which are the main cells in the dermis, and the synthetic functions of collagen, etc., decrease with exposure to various skin aging factors, especially sunlight (ultraviolet rays). And the turnover speed of this collagen etc. also becomes slow. As a result, the elasticity of the skin is lost, wrinkles are generated, and skin aging progresses.
しわ改善効果を有する物質については、アミノ酸の一種であるアラニンやグリシンが有効であることが知られていた(特許文献1及び特許文献2参照)。しかしながらこれらアラニン、グリシンは皮膚へ塗布した場合、非常な痛みを伴い、使用することが困難であった。 Regarding substances having wrinkle improving effects, it has been known that alanine and glycine, which are types of amino acids, are effective (see Patent Document 1 and Patent Document 2). However, when these alanine and glycine are applied to the skin, they are very painful and difficult to use.
本発明に係る3−(シクロヘキシルアミノ)プロパンスルホン酸については、生物学的に用いられるGood緩衝液(非特許文献1参照)の構成成分の1つとして記載されており、また、毛穴縮小の用途(特許文献3参照)が知られているが、しわ防止・改善効果を有することは新規である。 The 3- (cyclohexylamino) propanesulfonic acid according to the present invention is described as one of the components of the biologically used Good buffer (see Non-Patent Document 1), and is used for pore reduction. (See Patent Document 3) is known, but it has a novel effect of preventing and improving wrinkles.
また、本発明に係る3−(シクロヘキシルアミノ)−2−ヒドロキシプロパンスルホン酸については、やはり生物学的に用いる緩衝液の1つとして知られており(特許文献4及び5参照)、また、毛穴縮小効果の用途(特許文献3参照)が知られている。しかしながら、しわ防止・改善効果を有することは新規である。 In addition, 3- (cyclohexylamino) -2-hydroxypropanesulfonic acid according to the present invention is also known as one of biologically used buffers (see Patent Documents 4 and 5), and pores. The use of the reduction effect (see Patent Document 3) is known. However, it has a novel effect of preventing and improving wrinkles.
本発明は上記事情に鑑みてなされたもので、その目的は、しわの発生抑制効果またはしわの改善効果に優れる安全なしわ防止・改善剤を提供することにある。 The present invention has been made in view of the above circumstances, and an object thereof is to provide a safe wrinkle prevention / improving agent that is excellent in the effect of suppressing the generation of wrinkles or the effect of improving wrinkles.
本発明者らは上記課題を解決するために、鋭意研究を重ねた結果、特定のアミノ硫酸化合物及びその塩が、優れたしわを防止し、また改善する効果を発揮し、かつ安全な物質であり、上記課題が解決されることを見出し、本発明を完成するに至った。 As a result of intensive studies to solve the above problems, the present inventors have found that a specific aminosulfuric acid compound and a salt thereof have an effect of preventing and improving excellent wrinkles, and are a safe substance. The present inventors have found that the above problems can be solved, and have completed the present invention.
すなわち、本発明は、下記一般式(1)で示されるアミノ硫酸化合物及びその塩からなる群から選ばれる化合物の1種又は2種以上を含有するしわ防止・改善剤である。 That is, the present invention is a wrinkle prevention / improving agent containing one or more compounds selected from the group consisting of aminosulfuric acid compounds represented by the following general formula (1) and salts thereof.
(一般式(1)中、R1は水素原子または水酸基を表す。) (In general formula (1), R 1 represents a hydrogen atom or a hydroxyl group.)
本発明によれば、優れたしわ防止・改善効果を有するしわ防止・改善剤が得られる。 According to the present invention, a wrinkle prevention / improving agent having an excellent wrinkle prevention / improvement effect can be obtained.
以下、本発明を実施するための最良の形態について詳述する。 Hereinafter, the best mode for carrying out the present invention will be described in detail.
本発明においては、下記一般式(1)で示されるアミノ硫酸化合物及びその塩からなる群から選ばれる化合物の1種又は2種以上が用いられる。 In the present invention, one or more compounds selected from the group consisting of aminosulfuric acid compounds represented by the following general formula (1) and salts thereof are used.
(一般式(1)中、R1は水素原子または水酸基を表す。) (In general formula (1), R 1 represents a hydrogen atom or a hydroxyl group.)
前記一般式(1)で示されるアミノ硫酸化合物において、R1が水素原子の場合は、3−(シクロヘキシルアミノ)プロパンスルホン酸であり、一般にCAPSの名称で知られている公知の化合物である。また、R1が水酸基の場合は、3−(シクロヘキシルアミノ)−2−ヒドロキシプロパンスルホン酸であり、一般にCAPSOの名称で知られている公知の化合物である。本発明において用いられる一般式(1)で示されるアミノ硫酸化合物は、公知の方法により合成することが可能で、またシグマ社等から市販されており、それを使用することも可能である。 In the aminosulfuric acid compound represented by the general formula (1), when R 1 is a hydrogen atom, it is 3- (cyclohexylamino) propanesulfonic acid, which is a known compound generally known by the name of CAPS. When R 1 is a hydroxyl group, it is 3- (cyclohexylamino) -2-hydroxypropanesulfonic acid, and is a known compound generally known by the name of CAPSO. The aminosulfuric acid compound represented by the general formula (1) used in the present invention can be synthesized by a known method, and is commercially available from Sigma or the like, and can be used.
前記一般式(1)で示されるアミノ硫酸化合物の塩としては、特に限定されないが、例えば、無機塩としては、塩酸塩、硫酸塩、リン酸塩、臭化水素酸塩、ナトリウム塩、カリウム塩、マグネシウム塩、カルシウム塩、アンモニウム塩等が挙げられる。有機塩としては、酢酸塩、乳酸塩、マレイン酸塩、フマル酸塩、酒石酸塩、クエン酸塩、メタンスルホン酸塩、p−トルエンスルホン酸塩、トリエタノールアミン塩、ジエタノールアミン塩、アミノ酸塩等が挙げられる。塩は公知の方法によって得ることができる。 The salt of the aminosulfuric acid compound represented by the general formula (1) is not particularly limited, but examples of the inorganic salt include hydrochloride, sulfate, phosphate, hydrobromide, sodium salt, and potassium salt. , Magnesium salt, calcium salt, ammonium salt and the like. Organic salts include acetate, lactate, maleate, fumarate, tartrate, citrate, methanesulfonate, p-toluenesulfonate, triethanolamine salt, diethanolamine salt, amino acid salt, etc. Can be mentioned. The salt can be obtained by a known method.
本発明に係る一般式(1)で示されるアミノ硫酸化合物及びその塩は、いずれも後で証明するように優れたしわ防止・改善効果を有する。したがって、一般式(1)で示されるアミノ硫酸化合物及びその塩からなる群から選ばれる化合物の1種又は2種以上を含有し、しわ防止・改善剤に調製される。 The aminosulfuric acid compound represented by the general formula (1) and the salt thereof according to the present invention have excellent wrinkle prevention / improvement effects as will be proved later. Therefore, it contains one or more compounds selected from the group consisting of the aminosulfuric acid compound represented by the general formula (1) and a salt thereof, and is prepared as a wrinkle prevention / improving agent.
前記しわ防止・改善剤は、前記本発明に係る一般式(1)で示されるアミノ硫酸化合物及びその塩の前記新規な機能の発見に基づく新規で有用な用途である。 The wrinkle prevention / improving agent is a new and useful application based on the discovery of the novel function of the aminosulfuric acid compound represented by the general formula (1) and the salt thereof according to the present invention.
前記しわ防止・改善剤において、前記一般式(1)で示されるアミノ硫酸化合物及びその塩からなる群から選ばれる化合物の1種又は2種以上はしわ防止・改善作用を発揮するに有効な量が含有されるが、その含有量は、しわ防止・改善剤全量中0.001〜20.0質量%であることが好ましい。さらに好ましくは0.1〜10.0質量%である。 In the wrinkle prevention / improving agent, one or more compounds selected from the group consisting of the aminosulfuric acid compound represented by the general formula (1) and a salt thereof are effective in exhibiting the wrinkle prevention / amelioration action. However, the content is preferably 0.001 to 20.0% by mass in the total amount of the wrinkle prevention / improving agent. More preferably, it is 0.1-10.0 mass%.
本発明に係るしわ防止・改善剤は、常法に従って製造することができ、またしわ防止・改善剤を構成する成分として、前記一般式(1)で示されるアミノ硫酸化合物及びその塩からなる群から選ばれる化合物の1種又は2種以上単独でも調製可能であるが、通常本発明の効果を損なわない範囲で、医薬部外品を含む化粧品や医薬品等の皮膚外用剤等に用いられる他の成分を、必要に応じて適宜配合することができる。前記他の成分(任意配合成分)としては、例えば、油分、界面活性剤、粉末、色材、水、アルコール類、シリコーン類、増粘剤、キレート剤、酸化防止剤、紫外線吸収剤、保湿剤、香料、各種薬効成分、防腐剤、pH調整剤、中和剤等が挙げられる。 The wrinkle prevention / improving agent according to the present invention can be produced according to a conventional method, and as a component constituting the wrinkle prevention / improving agent, a group consisting of the aminosulfuric acid compound represented by the general formula (1) and salts thereof One or two or more of the compounds selected from the above can be prepared alone, but other than those usually used for skin external preparations such as cosmetics and pharmaceuticals including quasi-drugs, as long as the effects of the present invention are not impaired. The components can be appropriately blended as necessary. Examples of the other components (optional blending components) include oils, surfactants, powders, coloring materials, water, alcohols, silicones, thickeners, chelating agents, antioxidants, ultraviolet absorbers, and humectants. , Fragrances, various medicinal ingredients, preservatives, pH adjusters, neutralizers and the like.
前記しわ防止・改善剤は、化粧料、医薬組成物等の形態で使用され、優れたしわ防止・改善効果を発揮する。特に、好適には化粧品、医薬品等に応用されて、皮膚に外用される皮膚外用剤の形態で、皮膚に直接塗布又は散布する投与方法により使用され、優れたしわ防止・改善効果を発揮する。 The wrinkle prevention / improving agent is used in the form of cosmetics, pharmaceutical compositions, etc., and exhibits an excellent wrinkle prevention / improvement effect. In particular, it is preferably applied to cosmetics, pharmaceuticals, etc., and is used in a form of an external preparation for skin that is externally applied to the skin.
本発明のしわ防止・改善剤は肌に適用することでしわの形成の予防及び/又は形成されたしわの軽減・消失を図るための美容方法に利用できる。かかる美容方法における本発明のしわ防止・改善剤の用法、用量は特に限定されるものではなく、剤型や処置する肌のしわの状態により適宜決定されるが、典型的には、1日当たり数回、例えば1回〜5回、適量、例えば1cm2当たり0.1mlから1ml、肌に直接すり込むか、又その適量をガーゼ等に染み込ませてから肌に貼付して使用することができる。 The wrinkle prevention / improving agent of the present invention can be applied to the skin to prevent wrinkle formation and / or reduce or eliminate wrinkles formed. The usage and dosage of the wrinkle prevention / improving agent of the present invention in such a cosmetic method is not particularly limited and is appropriately determined depending on the dosage form and the state of wrinkles on the skin to be treated. Applicable amount, for example, 1 to 5 times, for example, 0.1 ml to 1 ml per 1 cm 2 , can be directly rubbed into the skin, or the appropriate amount can be soaked in gauze or the like and applied to the skin.
前記しわ防止・改善剤の剤型としては、本発明の効果を発揮できるものであれば特に限定されず、例えば、溶液系、可溶化系、乳化系、粉末分散系、水−油二層系、水−油−粉末三層系、軟膏、ゲル、エアゾール等任意の剤型をとることができる。 The dosage form of the wrinkle prevention / improving agent is not particularly limited as long as it can exert the effects of the present invention, and examples thereof include a solution system, a solubilization system, an emulsification system, a powder dispersion system, and a water-oil two-layer system. , Water-oil-powder three-layer system, ointment, gel, aerosol, etc.
前記しわ防止・改善剤は、例えば、医薬部外品を含む化粧品、医薬品の分野で応用され、その製品形態としては、例えば、軟膏、クリーム、乳液、化粧水、エッセンス、ゼリー、ジェル、パック、マスク、ファンデーション等の任意の形態をとることができる。 The wrinkle prevention / improving agent is applied, for example, in the field of cosmetics including quasi-drugs and pharmaceuticals, and the product forms include, for example, ointments, creams, emulsions, lotions, essences, jellies, gels, packs, Arbitrary forms such as a mask and a foundation can be taken.
本発明を実施例等により具体的に説明するが、これらの実施例等により本発明の技術的範囲が限定されるものではない。配合量は特に断りのない限り質量%である。 The present invention will be specifically described with reference to examples, but the technical scope of the present invention is not limited to these examples. The blending amount is mass% unless otherwise specified.
[ヘアレスマウスでのしわ改善試験]
マウスはHr−1(Skh−1)ヘアレスマウス(星野実験動物;6週齢〜10週齢)を用い、シュワルツらの方法(Haratake A. et al. J. Invest. Dermatol. 108:769-775, 1997.)を一部変えて、UVBを繰り返し照射する方法(Naganuma M. et al. J. Dermatol. Sci. 25:29-35, 2001. Schwartz E. J. Invest. Dermatol. 91:158-161, 1988.)に準じてしわを形成させた。すなわち背部にUVB(光源;東芝エレクトリック製 東芝 FL−20 SE蛍光ランプ)を週3回、10週間照射した。開始後の照射量は36mJ/cm2/回とし、2週目以降は徐々に増加させ、10週目は216mJ/cm2/回とした。総照射量は4.6J/cm2であった。紫外線量はUVRADIOMETER(UVR−305/365D(II)、トプコン)にて測定した値を用いた。紫外線照射を終了し、マウス背部の写真を撮影し、ビセットらの方法(Bissett DL. et al. Photochemistry and Photobiology 46: 367-378,1987.)を一部変えた方法でしわの生成度合いを下記の表1に示す判定基準に従ってスコア化し、評点7以上のしわを形成したマウスのみを用いて、以下の溶液を塗布した。しわのスコア化作業は3名の測定者が個別に行い、合議によって評点を決定した。
[Wrinkle improvement test with hairless mice]
As a mouse, an Hr-1 (Skh-1) hairless mouse (Hoshino experimental animal; 6 weeks to 10 weeks old) was used, and the method of Schwartz et al. (Haratake A. et al. J. Invest. Dermatol. 108: 769-775). , 1997.), a method of repeated irradiation with UVB (Naganuma M. et al. J. Dermatol. Sci. 25: 29-35, 2001. Schwartz EJ Invest. Dermatol. 91: 158-161, 1988 .) Wrinkles were formed. That is, the back was irradiated with UVB (light source; Toshiba FL-20 SE fluorescent lamp manufactured by Toshiba Electric) three times a week for 10 weeks. Irradiation amount after the start of the 36mJ / cm 2 / times, 2 weeks later is gradually increased, 10 weeks was 216mJ / cm 2 / times. The total irradiation dose was 4.6 J / cm 2 . The amount of ultraviolet rays used was a value measured with UVRADIOMETER (UVR-305 / 365D (II), Topcon). After UV irradiation was completed, a photo of the back of the mouse was taken, and the degree of wrinkle formation was determined using a method that partially modified Biset et al.'S method (Bissett DL. Et al. Photochemistry and Photobiology 46: 367-378, 1987). The following solutions were applied using only mice that were scored according to the criteria shown in Table 1 and formed wrinkles with a score of 7 or higher. The wrinkle scoring work was done individually by three measurers, and the score was determined by discussion.
評点7以上のヘアレスマウスを5匹ずつ2群に、かつ両群の評点が同じになるように分け、各群のマウス背部皮膚全体に下記組成を示す比較例1の組成物又は実施例1の組成物それぞれ100μlを1日1回、週5回、6週間連続塗布した。 The hairless mice having a score of 7 or more were divided into 2 groups of 5 each so that the scores of both groups were the same, and the composition of Comparative Example 1 or Example 1 showing the following composition on the entire back skin of each group of mice 100 μl of each composition was applied once a day, 5 times a week for 6 weeks continuously.
[実施例1]組成物
成分 配合量(質量%)
CAPSO 1.0
化粧品用エタノール 30.0
精製水 残余
[Example 1] Composition component Amount (% by mass)
CAPSO 1.0
Ethanol for cosmetics 30.0
Purified water residue
[比較例1]組成物
成分 配合量(質量%)
化粧品用エタノール 30.0
精製水 残余
[Comparative Example 1] Composition component amount (% by mass)
Ethanol for cosmetics 30.0
Purified water residue
塗布終了後、マウス背部の写真を撮影し、上記表1に示した判定基準に従って、動物の群名を伏せた状態でしわの度合いを3名の測定者が個別にスコア化し、合議によって評点を決定した。 After the application, a photograph of the back of the mouse was taken, and according to the criteria shown in Table 1 above, the three measurers scored the degree of wrinkles individually with the group name of the animal lying down, and scored by discussion. Were determined.
マウスのしわの改善度は次のようにして求めた。すなわち、
「しわ改善度」=「溶液塗布前の評点」−「6週間溶液塗布後の評点」
の式によって算出した。図1に上記式に従って得たしわ改善度(しわ改善変化量)を示した。なお、図1中、Aは実施例1(CAPSO配合)の組成物であり、Vは比較例1(薬剤無配合)の組成物である。
The degree of improvement of the wrinkle of the mouse was determined as follows. That is,
“Wrinkle improvement” = “Score before solution application” − “Score after 6 weeks of solution application”
It was calculated by the following formula. FIG. 1 shows the degree of wrinkle improvement (wrinkle improvement change amount) obtained according to the above formula. In FIG. 1, A is the composition of Example 1 (with CAPSO), and V is the composition of Comparative Example 1 (with no drug).
図1より明らかなように、比較例1(薬剤無配合)の組成物塗布群(平均評点:2.4)に対し本発明の実施例1(CAPSO)の組成物塗布群(平均評点:3.4)では、しわの減少は顕著に促進された。以上より、CAPSO溶液には紫外線により形成された皮膚のしわ改善に効果があることが確認された。 As is apparent from FIG. 1, the composition application group (average score: 3) of Example 1 (CAPSO) of the present invention is compared to the composition application group (average score: 2.4) of Comparative Example 1 (no drug blended). .4) markedly promoted wrinkle reduction. From the above, it was confirmed that the CAPSO solution is effective in improving wrinkles on the skin formed by ultraviolet rays.
[ヒトしわ改善効果試験]
(試験方法)
下記に組成を示す実施例2〜9と比較例2の組成物(クリーム)のしわ及び小じわ改善効果について、以下のように実施した。40〜60代のしわの多い女性被験者180名で、1群20名に分けて9群とし、上記実施例及び比較例の組成物(クリーム)9品それぞれを各群の20名の顔面目尻に2ヵ月間連用させた。連用後、美容技術者によるしわ及び小じわの状態の視感評価を実施し、著効、有効、やや有効、無効の4段階で評価し、以下の基準によりしわ改善効果を判定した。
[Human wrinkle improvement effect test]
(Test method)
About the wrinkle and fine wrinkle improvement effect of the composition (cream) of Examples 2-9 which show a composition below and Comparative Example 2, it implemented as follows. There are 180 female subjects with many wrinkles in their 40s and 60s, divided into 20 groups per group and 9 groups. Each of the 9 compositions (creams) of the above examples and comparative examples is applied to the 20 eyes of each group. Used continuously for 2 months. After continuous use, a cosmetic engineer evaluated wrinkles and fine wrinkles, and evaluated in four stages: marked, effective, slightly effective, and ineffective, and judged wrinkle improvement effect according to the following criteria.
著効:しわ及び小じわがほとんど目立たなくなった。
有効:しわ及び小じわがかなり目立たなくなった。
やや有効:しわ及び小じわが試験前よりも目立たなくなった。
無効:変化なし。
Remarkable: Wrinkles and fine lines are almost inconspicuous.
Effective: Wrinkles and fine lines became inconspicuous.
Slightly effective: Wrinkles and fine lines became less noticeable than before the test.
Invalid: No change.
(判定)
優:被験者のうち著効、有効及びやや有効の示す割合が80%以上。
良:被験者のうち著効、有効及びやや有効の示す割合が50%以上、80%未満。
可:被験者のうち著効、有効及びやや有効の示す割合が30%以上、50%未満。
不可:被験者のうち著効、有効及びやや有効の示す割合が30%未満。
(Judgment)
Excellent: 80% or more of subjects exhibiting remarkable, effective, and slightly effective.
Good: The proportion of subjects showing remarkable, effective and slightly effective is 50% or more and less than 80%.
Acceptable: The proportion of subjects who are markedly effective, effective and slightly effective is 30% or more and less than 50%.
Impossible: The proportion of subjects showing remarkable, effective and slightly effective is less than 30%.
実施例2〜9及び比較例2組成物(クリーム)
成分 配合量(質量%)
A(油相)
スクワラン 15.0
ワセリン 7.0
セタノール 4.0
イソプロピルミリステート 8.0
ステアリン酸モノグリセリンエステル 2.0
POE(20)ソルビタンモノステアレート 2.0
ビタミンEアセテート 1.0
エチルパラベン 0.2
香料 0.2
B(水相)
グリセリン 4.0
ジプロピレングリコール 4.0
しわ防止・改善剤(下記表2記載) 下記表2記載
乳酸ナトリウム 2.0
エデト酸三ナトリウム 0.01
水酸化カリウム 0.2
精製水 残余
Examples 2 to 9 and Comparative Example 2 Composition (Cream)
Ingredient Amount (% by mass)
A (oil phase)
Squalane 15.0
Vaseline 7.0
Cetanol 4.0
Isopropyl myristate 8.0
Stearic acid monoglycerin ester 2.0
POE (20) sorbitan monostearate 2.0
Vitamin E acetate 1.0
Ethylparaben 0.2
Fragrance 0.2
B (water phase)
Glycerin 4.0
Dipropylene glycol 4.0
Wrinkle prevention / improving agent (described in Table 2 below) Sodium lactate described in Table 2 2.0
Edetate trisodium 0.01
Potassium hydroxide 0.2
Purified water residue
(製法)A(油相)とB(水相)をそれぞれ70℃に加熱して完全に溶解した。AをBに加えて乳化機で乳化した。乳化物を熱交換機を用いて冷却して組成物(クリーム)を製造した。 (Production Method) A (oil phase) and B (aqueous phase) were each heated to 70 ° C. and completely dissolved. A was added to B and emulsified with an emulsifier. The emulsion was cooled using a heat exchanger to produce a composition (cream).
(試験結果)
試験結果を表3に示した。
(Test results)
The test results are shown in Table 3.
表3から明らかなように、本発明に係る実施例2〜9組成物(クリーム)は優れたしわ改善効果を有していることが分かる。 As is clear from Table 3, it can be seen that the compositions (creams) of Examples 2 to 9 according to the present invention have an excellent wrinkle improving effect.
以下に本発明に係るしわ防止・改善剤の製剤例として皮膚外用剤を示す。なお、いずれの皮膚外用剤も優れたしわ防止・改善効果を有していた。 The following is an external preparation for skin as a preparation example of the wrinkle prevention / improving agent according to the present invention. All of the external preparations for skin had excellent wrinkle prevention and improvement effects.
製剤例1:しわ防止・改善用クリーム
成分 配合量(質量%)
ステアリン酸 5.0
ステアリルアルコール 4.0
イソプロピルミリステート 18.0
グリセリンモノステアリン酸エステル 3.0
プロピレングリコール 10.0
CAPSO 20.0
苛性カリ 0.2
亜硫酸水素ナトリウム 0.01
防腐剤 適量
香料 適量
イオン交換水 残余
Formulation Example 1: Wrinkle prevention / improvement cream ingredient content (% by mass)
Stearic acid 5.0
Stearyl alcohol 4.0
Isopropyl myristate 18.0
Glycerol monostearate 3.0
Propylene glycol 10.0
CAPSO 20.0
Caustic potash 0.2
Sodium bisulfite 0.01
Preservative Appropriate amount of perfume Appropriate amount of ion-exchanged water
(製法)イオン交換水にプロピレングリコールと苛性カリを加え溶解し加熱して70℃に保った(水相)。他の成分を混合し加熱融解して70℃に保った(油相)。水相に油相を徐々に加え、全部加え終わってからしばらくその温度に保ち反応を起こさせた。その後ホモミキサーで均一に乳化し、よくかきまぜながら30℃まで冷却して製造した。 (Production method) Propylene glycol and caustic potash were added to ion-exchanged water, dissolved, heated and maintained at 70 ° C (water phase). The other ingredients were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was gradually added to the aqueous phase, and after the addition was completed, the temperature was maintained for a while to cause the reaction. Thereafter, the mixture was uniformly emulsified with a homomixer and cooled to 30 ° C. while stirring well.
製剤例2:しわ防止・改善用クリーム
成分 配合量(質量%)
ステアリン酸 6.0
ソルビタンモノステアリン酸エステル 2.0
ポリオキシエチレン(20モル)
ソルビタンモノステアリン酸エステル 1.5
プロピレングリコール 10.0
CAPS 7.0
グリセリントリオクタノエート 10.0
スクワレン 5.0
亜硫酸水素ナトリウム 0.01
エチルパラベン 0.3
香料 適量
イオン交換水 残余
Formulation Example 2: Wrinkle prevention / improvement cream component Amount (% by mass)
Stearic acid 6.0
Sorbitan monostearate ester 2.0
Polyoxyethylene (20 mol)
Sorbitan monostearate 1.5
Propylene glycol 10.0
CAPS 7.0
Glycerin trioctanoate 10.0
Squalene 5.0
Sodium bisulfite 0.01
Ethylparaben 0.3
Perfume Appropriate amount of ion-exchanged water
(製法)イオン交換水にプロピレングリコールを加え溶解し加熱して70℃に保つ(水相)。他の成分を混合し加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却して製造した。 (Production method) Propylene glycol is added to ion-exchanged water, dissolved, heated and maintained at 70 ° C (aqueous phase). The other ingredients were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, pre-emulsified, and uniformly emulsified with a homomixer, and then cooled to 30 ° C. while stirring well.
製剤例3:しわ防止・改善用クリーム
成分 配合量(質量%)
ステアリルアルコール 7.0
ステアリン酸 2.0
水添ラノリン 2.0
スクワラン 5.0
2−オクチルドデシルアルコール 6.0
ポリオキシエチレン(25モル)セチルアルコールエーテル 3.0
グリセリンモノステアリン酸エステル 2.0
プロピレングリコール 5.0
CAPSO 0.001
香料 適量
亜硫酸水素ナトリウム 0.03
エチルパラベン 0.3
イオン交換水 残余
Formulation Example 3: Wrinkle prevention / improvement cream component Amount (mass%)
Stearyl alcohol 7.0
Stearic acid 2.0
Hydrogenated Lanolin 2.0
Squalane 5.0
2-Octyldodecyl alcohol 6.0
Polyoxyethylene (25 mol) cetyl alcohol ether 3.0
Glycerin monostearate ester 2.0
Propylene glycol 5.0
CAPSO 0.001
Perfume proper amount Sodium bisulfite 0.03
Ethylparaben 0.3
Ion exchange water
(製法)イオン交換水にプロピレングリコールを加え溶解し加熱して70℃に保った(水相)。他の成分を混合し加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却して製造した。 (Manufacturing method) Propylene glycol was added to ion-exchanged water, dissolved, heated and maintained at 70 ° C (aqueous phase). The other ingredients were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, preliminarily emulsified, and uniformly emulsified with a homomixer, and then cooled to 30 ° C. while stirring well.
製剤例4:しわ防止・改善用乳液
成分 配合量(質量%)
ステアリン酸 2.5
セチルアルコール 1.5
ワセリン 5.0
流動パラフィン 10.0
ポリオキシエチレン(10モル)モノオレイン酸エステル 2.0
ポリエチレングリコ−ル1500 3.0
トリエタノールアミン 1.0
CAPS 10.0
亜硫酸水素ナトリウム 0.01
エチルパラベン 0.3
カルボキシビニルポリマー 0.05
香料 適量
イオン交換水 残余
Formulation Example 4: Wrinkle prevention / improvement emulsion component content (% by mass)
Stearic acid 2.5
Cetyl alcohol 1.5
Vaseline 5.0
Liquid paraffin 10.0
Polyoxyethylene (10 mol) monooleate 2.0
Polyethylene glycol 1500 3.0
Triethanolamine 1.0
CAPS 10.0
Sodium bisulfite 0.01
Ethylparaben 0.3
Carboxyvinyl polymer 0.05
Perfume Appropriate amount of ion-exchanged water
(製法)少量のイオン交換水にカルボキシビニルポリマーを溶解した(A相)。残りのイオン交換水にポリエチレングリコール1500とトリエタノールアミンを加え加熱溶解して70℃に保った(水相)。他の成分を混合し加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、A相を加えホモミキサーで均一に乳化し、乳化後よくかきまぜながら30℃まで冷却して製造した。 (Production method) A carboxyvinyl polymer was dissolved in a small amount of ion-exchanged water (phase A). Polyethylene glycol 1500 and triethanolamine were added to the remaining ion-exchanged water, dissolved by heating and kept at 70 ° C. (aqueous phase). The other ingredients were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase for preliminary emulsification, and the A phase was added, and the mixture was uniformly emulsified with a homomixer.
製剤例5:しわ防止・改善用乳液
成分 配合量(質量%)
(油相部)
ステアリルアルコール 1.5
スクワレン 2.0
ワセリン 2.5
脱臭液状ラノリン 1.5
月見草油 2.0
ミリスチン酸イソプロピル 5.0
グリセリンモノオレート 2.0
ポリオキシエチレン(60モル)硬化ヒマシ油 2.0
酢酸トコフェロール 0.05
エチルパラベン 0.2
ブチルパラベン 0.1
エチルグリシン 1.0
CAPSO 1.0
香料 適量
(水相部)
亜硫酸水素ナトリウム 0.01
グリセリン 5.0
ヒアルロン酸ナトリウム 0.01
カルボキシビニルポリマー 0.2
水酸化カリウム 0.2
精製水 残余
Formulation Example 5: Wrinkle prevention / improvement emulsion component content (% by mass)
(Oil phase)
Stearyl alcohol 1.5
Squalene 2.0
Vaseline 2.5
Deodorized liquid lanolin 1.5
Evening primrose oil 2.0
Isopropyl myristate 5.0
Glycerol monooleate 2.0
Polyoxyethylene (60 mol) hydrogenated castor oil 2.0
Tocopherol acetate 0.05
Ethylparaben 0.2
Butylparaben 0.1
Ethylglycine 1.0
CAPSO 1.0
Perfume appropriate amount (water phase part)
Sodium bisulfite 0.01
Glycerin 5.0
Sodium hyaluronate 0.01
Carboxyvinyl polymer 0.2
Potassium hydroxide 0.2
Purified water residue
(製法)油相部を70℃にて溶解した。水相部を70℃にて溶解し、水相部に油相部を混合し、乳化機で乳化後熱交換機で30℃まで冷却して製造した。 (Manufacturing method) The oil phase part was melt | dissolved at 70 degreeC. The water phase part was dissolved at 70 ° C., the oil phase part was mixed with the water phase part, emulsified with an emulsifier and then cooled to 30 ° C. with a heat exchanger.
製剤例6:しわ防止・改善用ゼリー
成分 配合量(質量%)
95%エチルアルコール 10.0
ジプロピレングリコール 15.0
ポリオキシエチレン(50モル)オレイルアルコールエーテル 2.0
カルボキシビニルポリマー 1.0
苛性ソーダ 0.15
L−アルギニン 0.1
CAPS 1.0
メチルパラベン 0.2
香料 適量
イオン交換水 残余
Formulation Example 6: Wrinkle prevention / improvement jelly component content (mass%)
95% ethyl alcohol 10.0
Dipropylene glycol 15.0
Polyoxyethylene (50 mol) oleyl alcohol ether 2.0
Carboxyvinyl polymer 1.0
Caustic soda 0.15
L-Arginine 0.1
CAPS 1.0
Methylparaben 0.2
Perfume Appropriate amount of ion-exchanged water
(製法)イオン交換水にカルボキシビニルポリマーを均一に溶解し、一方、95%エタノールにサルコシン、ポリオキシエチレン(50モル)オレイルアルコールエーテルを溶解し、水相に添加した。次いで、その他の成分を加えた後、苛性ソーダ、L−アルギニンで中和させ増粘して製造した。 (Production Method) Carboxyvinyl polymer was uniformly dissolved in ion-exchanged water, while sarcosine and polyoxyethylene (50 mol) oleyl alcohol ether were dissolved in 95% ethanol and added to the aqueous phase. Subsequently, other components were added, and the mixture was neutralized with caustic soda and L-arginine to increase the viscosity.
製剤例7:しわ防止・改善用美容液
成分 配合量(質量%)
(A相)
エタノール(95%) 10.0
ポリオキシエチレン(20モル)オクチルドデカノール 1.0
メチルパラベン 0.15
パントテニールエチルエーテル 0.1
CAPS 0.05
(B相)
水酸化カリウム 0.1
(C相)
グリセリン 5.0
ジプロピレングリコール 10.0
亜硫酸水素ナトリウム 0.03
カルボキシビニルポリマー 0.2
精製水 残余
Formulation Example 7: Essence ingredient for wrinkle prevention / improvement Blending amount (% by mass)
(Phase A)
Ethanol (95%) 10.0
Polyoxyethylene (20 mol) octyldodecanol 1.0
Methylparaben 0.15
Pantotenyl ethyl ether 0.1
CAPS 0.05
(Phase B)
Potassium hydroxide 0.1
(Phase C)
Glycerin 5.0
Dipropylene glycol 10.0
Sodium bisulfite 0.03
Carboxyvinyl polymer 0.2
Purified water residue
(製法)A相、C相をそれぞれ均一に溶解し、C相にA相を加えて可溶化した。次いで、B相を加えた後充填を行い製造した。 (Manufacturing method) The A phase and the C phase were uniformly dissolved, and the A phase was added to the C phase and solubilized. Subsequently, after adding B phase, it filled and manufactured.
製剤例8:しわ防止・改善用パック
成分 配合量(質量%)
(A相)
ジプロピレングリコール 5.0
ポリオキシエチレン(60モル)硬化ヒマシ油 5.0
(B相)
CAPS 1.0
オリーブ油 5.0
酢酸トコフェノール 0.2
エチルパラベン 0.2
香料 0.2
(C相)
亜硫酸水素ナトリウム 0.03
ポリビニルアルコール(ケン化度90、重合度2000) 13.0
エタノール 7.0
精製水 残余
Formulation Example 8: Wrinkle prevention / improvement pack component Amount (% by mass)
(Phase A)
Dipropylene glycol 5.0
Polyoxyethylene (60 mol) hydrogenated castor oil 5.0
(Phase B)
CAPS 1.0
Olive oil 5.0
Tocophenol acetate 0.2
Ethylparaben 0.2
Fragrance 0.2
(Phase C)
Sodium bisulfite 0.03
Polyvinyl alcohol (degree of saponification 90, degree of polymerization 2000) 13.0
Ethanol 7.0
Purified water residue
(製法)A相、B相、C相をそれぞれ均一に溶解し、A相にB相を加えて可溶化した。ついで、これをC相に加えた後充填を行い製造した。 (Manufacturing method) A phase, B phase, and C phase were each dissolved uniformly, and B phase was added to A phase to solubilize. Subsequently, after adding this to the C phase, it filled and manufactured.
製剤例9:しわ防止・改善用軟膏
成分 配合量(質量%)
ポリオキシエチレン(30モル)セチルエーテル 2.0
グリセリンモノステアレート 10.0
流動パラフィン 10.0
ワセリン 40.0
セタノール 6.0
メチルパラベン 0.1
ブチルパラベン 0.1
グリセリンモノステアリン酸エステル 2.0
CAPS 5.0
CAPSO 5.0
プロピレングリコール 10.0
イオン交換水 残余
香料 適量
Formulation Example 9: Ointment component for preventing and improving wrinkles
Polyoxyethylene (30 mol) cetyl ether 2.0
Glycerol monostearate 10.0
Liquid paraffin 10.0
Vaseline 40.0
Cetanol 6.0
Methylparaben 0.1
Butylparaben 0.1
Glycerin monostearate ester 2.0
CAPS 5.0
CAPSO 5.0
Propylene glycol 10.0
Ion exchange water Residual perfume appropriate amount
(製法)イオン交換水にプロピレングリコールを加え、溶解し加熱して70℃に保った(水相)。他の成分を70℃にて混合溶解した(油相)。上記水相に油相を添加し、ホモミキサーで均一に乳化し、冷却後充填を行い製造した。 (Production Method) Propylene glycol was added to ion-exchanged water, dissolved, heated and kept at 70 ° C. (aqueous phase). Other components were mixed and dissolved at 70 ° C. (oil phase). An oil phase was added to the aqueous phase, and the mixture was uniformly emulsified with a homomixer, and filled after cooling.
以下、同様にしてクリームを製造した。 Thereafter, creams were produced in the same manner.
製剤例10:しわ防止・改善用クリーム
成分 配合量(質量%)
流動パラフィン 8.0
ワセリン 3.0
ジメチルポリシロキサン 2.0
ステアリルアルコール 3.0
ベヘニルアルコール 2.0
グリセリン 5.0
ジプロピレングリコール 4.0
トレハロース 1.0
テトラ2−エチルヘキサン酸ペンタエリスリット 4.0
モノイソステアリン酸ポリオキシエチレングリセリル 2.0
モノステアリン酸ポリオキシエチレングリセリン 1.0
親油型モノステアリン酸グリセリン 2.0
クエン酸 0.05
クエン酸ナトリウム 0.05
水酸化カリウム 0.015
油溶性甘草エキス 0.1
レチノールパルミテート(100万単位) 0.25
CAPS 1.0
CAPSO 1.0
酢酸トコフェロール 0.1
パラオキシ安息香酸エステル 適量
フェノキシエタノール 適量
ジブチルヒドロキシトルエン 適量
エデト酸三ナトリウム 0.05
4−t−ブチル−4’−メトキシジベンゾイルメタン 0.01
パラメトキシ桂皮酸2−エチルヘキシル 0.1
β−カロチン 0.01
ポリビニルアルコール 0.5
ヒドロキシエチルセルロース 0.5
カルボキシビニルポリマー 0.05
精製水 残余
香料 適量
Formulation Example 10: Cream component for wrinkle prevention / improvement Compounding amount (% by mass)
Liquid paraffin 8.0
Vaseline 3.0
Dimethylpolysiloxane 2.0
Stearyl alcohol 3.0
Behenyl alcohol 2.0
Glycerin 5.0
Dipropylene glycol 4.0
Trehalose 1.0
Tetra-2-ethylhexanoic acid pentaerythrit 4.0
Polyisoethylene glyceryl monoisostearate 2.0
Polyoxyethylene glycerol monostearate 1.0
Lipophilic glyceryl monostearate 2.0
Citric acid 0.05
Sodium citrate 0.05
Potassium hydroxide 0.015
Oil-soluble licorice extract 0.1
Retinol palmitate (1 million units) 0.25
CAPS 1.0
CAPSO 1.0
Tocopherol acetate 0.1
P-Hydroxybenzoate appropriate amount phenoxyethanol appropriate amount dibutylhydroxytoluene appropriate amount edetate trisodium 0.05
4-t-butyl-4′-methoxydibenzoylmethane 0.01
2-Ethylhexyl paramethoxycinnamate 0.1
β-carotene 0.01
Polyvinyl alcohol 0.5
Hydroxyethyl cellulose 0.5
Carboxyvinyl polymer 0.05
Purified water Residual fragrance Appropriate amount
製剤例11:しわ防止・改善用クリーム
成分 配合量(質量%)
ワセリン 2.0
ジメチルポリシロキサン 2.0
エタノール 5.0
ベヘニルアルコール 0.5
バチルアルコール 0.2
グリセリン 7.0
1,3−ブチレングリコール 5.0
ポリエチレングリコール20000 0.5
ホホバ油 3.0
スクワラン 2.0
ヒドロキシステアリン酸フィトステリル 0.5
テトラ2−エチルヘキサン酸ペンタエリスリット 1.0
ポリオキシエチレン硬化ヒマシ油 1.0
水酸化カリウム 0.1
ピロ亜硫酸ナトリウム 0.01
ヘキサメタリン酸ナトリウム 0.05
グリチルレチン酸ステアリル 0.1
パントテニルエチルエーテル 0.1
アルブチン 7.0
トラネキサム酸メチルアミド塩酸塩 11.0
CAPSO 1.0
酢酸トコフェロール 0.1
ヒアルロン酸ナトリウム 0.05
パラオキシ安息香酸エステル 適量
エデト酸三ナトリウム 0.05
4−t−ブチル−4’−メトキシジベンゾイルメタン 0.1
ジパラメトキシ桂皮酸モノ−2−エチルヘキサン酸グリセリル 0.1
黄酸化鉄 適量
キサンタンガム 0.1
カルボキシビニルポリマー 0.2
精製水 残余
Formulation Example 11 Wrinkle prevention / improvement cream ingredient blending amount (mass%)
Vaseline 2.0
Dimethylpolysiloxane 2.0
Ethanol 5.0
Behenyl alcohol 0.5
Batyl alcohol 0.2
Glycerin 7.0
1,3-butylene glycol 5.0
Polyethylene glycol 20000 0.5
Jojoba oil 3.0
Squalane 2.0
Phytosteryl hydroxystearate 0.5
Tetra-2-ethylhexanoic acid pentaerythrit 1.0
Polyoxyethylene hydrogenated castor oil 1.0
Potassium hydroxide 0.1
Sodium pyrosulfite 0.01
Sodium hexametaphosphate 0.05
Stearyl glycyrrhetinate 0.1
Pantothenyl ethyl ether 0.1
Arbutin 7.0
Tranexamic acid methylamide hydrochloride 11.0
CAPSO 1.0
Tocopherol acetate 0.1
Sodium hyaluronate 0.05
P-Hydroxybenzoate appropriate amount trisodium edetate 0.05
4-t-butyl-4'-methoxydibenzoylmethane 0.1
Diparamethoxycinnamic acid mono-2-ethylhexanoate glyceryl 0.1
Yellow iron oxide xanthane gum 0.1
Carboxyvinyl polymer 0.2
Purified water residue
製剤例12:しわ防止・改善用クリーム
成分 配合量(質量%)
ワセリン 2.0
ジメチルポリシロキサン 2.0
エタノール 5.0
ベヘニルアルコール 0.5
バチルアルコール 0.2
グリセリン 7.0
1,3−ブチレングリコール 5.0
ポリエチレングリコール20000 0.5
ホホバ油 3.0
スクワラン 2.0
ヒドロキシステアリン酸フィトステリル 0.5
テトラ2−エチルヘキサン酸ペンタエリスリット 1.0
ポリオキシエチレン硬化ヒマシ油 1.0
水酸化カリウム 0.1
ピロ亜硫酸ナトリウム 0.01
ヘキサメタリン酸ナトリウム 0.05
グリチルレチン酸ステアリル 0.1
パントテニルエチルエーテル 0.1
アルブチン 7.0
トラネキサム酸メチルアミド塩酸塩 11.0
CAPS 1.0
酢酸トコフェロール 0.1
ヒアルロン酸ナトリウム 0.05
パラオキシ安息香酸エステル 適量
エデト酸三ナトリウム 0.05
4−t−ブチル−4’−メトキシジベンゾイルメタン 0.1
ジパラメトキシ桂皮酸モノ−2−エチルヘキサン酸グリセリル 0.1
黄酸化鉄 適量
キサンタンガム 0.1
カルボキシビニルポリマー 0.2
精製水 残余
Formulation Example 12: Cream component for wrinkle prevention / improvement Blending amount (% by mass)
Vaseline 2.0
Dimethylpolysiloxane 2.0
Ethanol 5.0
Behenyl alcohol 0.5
Batyl alcohol 0.2
Glycerin 7.0
1,3-butylene glycol 5.0
Polyethylene glycol 20000 0.5
Jojoba oil 3.0
Squalane 2.0
Phytosteryl hydroxystearate 0.5
Tetra-2-ethylhexanoic acid pentaerythrit 1.0
Polyoxyethylene hydrogenated castor oil 1.0
Potassium hydroxide 0.1
Sodium pyrosulfite 0.01
Sodium hexametaphosphate 0.05
Stearyl glycyrrhetinate 0.1
Pantothenyl ethyl ether 0.1
Arbutin 7.0
Tranexamic acid methylamide hydrochloride 11.0
CAPS 1.0
Tocopherol acetate 0.1
Sodium hyaluronate 0.05
P-Hydroxybenzoate appropriate amount trisodium edetate 0.05
4-t-butyl-4'-methoxydibenzoylmethane 0.1
Diparamethoxycinnamic acid mono-2-ethylhexanoate glyceryl 0.1
Yellow iron oxide xanthane gum 0.1
Carboxyvinyl polymer 0.2
Purified water residue
製剤例13:しわ防止・改善用クリーム
成分 配合量(質量%)
ワセリン 2.0
ジメチルポリシロキサン 2.0
エタノール 5.0
ベヘニルアルコール 0.5
バチルアルコール 0.2
グリセリン 7.0
1,3−ブチレングリコール 5.0
ポリエチレングリコール20000 0.5
ホホバ油 3.0
スクワラン 2.0
ヒドロキシステアリン酸フィトステリル 0.5
テトラ2−エチルヘキサン酸ペンタエリスリット 1.0
ポリオキシエチレン硬化ヒマシ油 1.0
水酸化カリウム 0.1
ピロ亜硫酸ナトリウム 0.01
ヘキサメタリン酸ナトリウム 0.05
グリチルレチン酸ステアリル 0.1
パントテニルエチルエーテル 0.1
アルブチン 7.0
トラネキサム酸メチルアミド塩酸塩 11.0
CAPSO・ナトリウム 1.0
酢酸トコフェロール 0.1
ヒアルロン酸ナトリウム 0.05
パラオキシ安息香酸エステル 適量
エデト酸三ナトリウム 0.05
4−t−ブチル−4’−メトキシジベンゾイルメタン 0.1
ジパラメトキシ桂皮酸モノ−2−エチルヘキサン酸グリセリル 0.1
黄酸化鉄 適量
キサンタンガム 0.1
カルボキシビニルポリマー 0.2
精製水 残余
Formulation Example 13: Cream component for wrinkle prevention / improvement Blending amount (% by mass)
Vaseline 2.0
Dimethylpolysiloxane 2.0
Ethanol 5.0
Behenyl alcohol 0.5
Batyl alcohol 0.2
Glycerin 7.0
1,3-butylene glycol 5.0
Polyethylene glycol 20000 0.5
Jojoba oil 3.0
Squalane 2.0
Phytosteryl hydroxystearate 0.5
Tetra-2-ethylhexanoic acid pentaerythrit 1.0
Polyoxyethylene hydrogenated castor oil 1.0
Potassium hydroxide 0.1
Sodium pyrosulfite 0.01
Sodium hexametaphosphate 0.05
Stearyl glycyrrhetinate 0.1
Pantothenyl ethyl ether 0.1
Arbutin 7.0
Tranexamic acid methylamide hydrochloride 11.0
CAPSO sodium 1.0
Tocopherol acetate 0.1
Sodium hyaluronate 0.05
P-Hydroxybenzoate appropriate amount trisodium edetate 0.05
4-t-butyl-4'-methoxydibenzoylmethane 0.1
Diparamethoxycinnamic acid mono-2-ethylhexanoate glyceryl 0.1
Yellow iron oxide xanthane gum 0.1
Carboxyvinyl polymer 0.2
Purified water residue
製剤例1〜13で製造されたしわ防止・改善剤はいずれも実施例2〜9で行ったのと同様の試験においてしわ改善効果を示した。 All the wrinkle prevention / improving agents produced in Formulation Examples 1 to 13 showed wrinkle improvement effects in the same tests as in Examples 2 to 9.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006084879A JP4874686B2 (en) | 2006-03-27 | 2006-03-27 | Anti-wrinkle / improving agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006084879A JP4874686B2 (en) | 2006-03-27 | 2006-03-27 | Anti-wrinkle / improving agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007261948A JP2007261948A (en) | 2007-10-11 |
| JP4874686B2 true JP4874686B2 (en) | 2012-02-15 |
Family
ID=38635297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006084879A Expired - Fee Related JP4874686B2 (en) | 2006-03-27 | 2006-03-27 | Anti-wrinkle / improving agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4874686B2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11130650A (en) * | 1997-03-31 | 1999-05-18 | Shiseido Co Ltd | Desmosome decomposition promoter and horny layer releasing agent |
| JP4373318B2 (en) * | 2003-11-27 | 2009-11-25 | 株式会社資生堂 | Abnormal keratinization inhibitor and composition for external use on skin |
| BRPI0519243A2 (en) * | 2004-12-22 | 2009-01-06 | Neurochem Int Ltd | Methods and compositions for treating amyloid-related diseases |
-
2006
- 2006-03-27 JP JP2006084879A patent/JP4874686B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007261948A (en) | 2007-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5501758B2 (en) | Anti-wrinkle / improving agent | |
| US20110065794A1 (en) | Wrinkle-preventing and improving composition | |
| WO1997002803A1 (en) | External skin preparation | |
| JPWO1997002803A1 (en) | topical skin preparations | |
| JPH027287B2 (en) | ||
| JP2005120023A (en) | Skin care preparation | |
| JP2004175750A (en) | Dermopathy inhibitor and dermopathy improving agent, and skin care preparation for external use containing them | |
| CN101646416B (en) | Composition for external application to skin | |
| JPH07101844A (en) | Multilayered emulsion | |
| JPH11269034A (en) | Skin prepafation for external use for improving acne | |
| JP4828077B2 (en) | Topical skin preparation | |
| JP7355571B2 (en) | Composition | |
| JP3657068B2 (en) | Anti-photoaging agent and external preparation for skin | |
| JP4874686B2 (en) | Anti-wrinkle / improving agent | |
| JP3441387B2 (en) | Moisturizer, skin cosmetics and bath additives | |
| JP2005239623A (en) | Agent for ameliorating microvillus-like protrusion of keratinocyte | |
| JP4887050B2 (en) | Inadequate keratinization inhibitor, pore reducing agent | |
| JPH0692833A (en) | Skin external agent | |
| JP2017214343A (en) | Therapeutic agent for acne-vulgaris | |
| KR102646279B1 (en) | A composition having improved emulsion stability comprising hydroquinone | |
| JP2000063255A (en) | Preparation for external use for skin | |
| JPH10114642A (en) | Skin preparation for external use | |
| JP2003171226A (en) | Skin care preparation | |
| JP2003081806A (en) | Skin cosmetics | |
| JP2011148734A (en) | Use of angiotensin-converting enzyme inhibitor and/or angiotensin ii receptor blocker in wrinkle treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090305 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111122 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111124 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141202 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4874686 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |